|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SLC44A5 |
Gene summary for SLC44A5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SLC44A5 | Gene ID | 204962 |
| Gene name | solute carrier family 44 member 5 | |
| Gene Alias | CTL5 | |
| Cytomap | 1p31.1 | |
| Gene Type | protein-coding | GO ID | GO:0006629 | UniProtAcc | Q8NCS7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 204962 | SLC44A5 | RNA-P17T-P17T-2 | Human | Lung | IAC | 1.20e-03 | 6.47e-01 | 0.3371 |
| 204962 | SLC44A5 | RNA-P17T-P17T-4 | Human | Lung | IAC | 1.61e-08 | 9.20e-01 | 0.343 |
| 204962 | SLC44A5 | RNA-P17T-P17T-6 | Human | Lung | IAC | 5.58e-04 | 5.85e-01 | 0.3385 |
| 204962 | SLC44A5 | RNA-P17T-P17T-8 | Human | Lung | IAC | 2.31e-03 | 4.99e-01 | 0.3329 |
| 204962 | SLC44A5 | HTA12-23-1 | Human | Pancreas | PDAC | 2.25e-04 | 5.41e-01 | 0.3405 |
| 204962 | SLC44A5 | HTA12-25-1 | Human | Pancreas | PDAC | 2.41e-10 | 8.00e-01 | 0.313 |
| 204962 | SLC44A5 | HTA12-26-1 | Human | Pancreas | PDAC | 1.03e-14 | 7.87e-01 | 0.3728 |
| 204962 | SLC44A5 | HTA12-29-1 | Human | Pancreas | PDAC | 9.39e-39 | 8.57e-01 | 0.3722 |
| 204962 | SLC44A5 | HTA12-30-1 | Human | Pancreas | PDAC | 1.14e-02 | 8.13e-01 | 0.3671 |
| 204962 | SLC44A5 | HTA12-32-1 | Human | Pancreas | PDAC | 1.46e-03 | 9.05e-01 | 0.3624 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa052317 | Lung | IAC | Choline metabolism in cancer | 23/1053 | 98/8465 | 1.72e-03 | 9.66e-03 | 6.41e-03 | 23 |
| hsa0523112 | Lung | IAC | Choline metabolism in cancer | 23/1053 | 98/8465 | 1.72e-03 | 9.66e-03 | 6.41e-03 | 23 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SLC44A5 | SNV | Missense_Mutation | c.37G>C | p.Glu13Gln | p.E13Q | protein_coding | tolerated(0.28) | benign(0.131) | TCGA-A8-A08L-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
| SLC44A5 | SNV | Missense_Mutation | c.1223N>T | p.Pro408Leu | p.P408L | protein_coding | tolerated(0.07) | benign(0.021) | TCGA-B6-A0RE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| SLC44A5 | SNV | Missense_Mutation | novel | c.463N>T | p.Pro155Ser | p.P155S | protein_coding | tolerated(0.37) | benign(0.001) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| SLC44A5 | SNV | Missense_Mutation | c.394N>G | p.Gln132Glu | p.Q132E | protein_coding | tolerated(0.14) | benign(0.003) | TCGA-E2-A150-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
| SLC44A5 | deletion | Frame_Shift_Del | c.1332delN | p.Gly445GlufsTer24 | p.G445Efs*24 | protein_coding | TCGA-E9-A22G-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||||
| SLC44A5 | SNV | Missense_Mutation | novel | c.1130N>A | p.Thr377Asn | p.T377N | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-EK-A2RM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| SLC44A5 | SNV | Missense_Mutation | novel | c.526N>G | p.Lys176Glu | p.K176E | protein_coding | tolerated(0.17) | benign(0.005) | TCGA-VS-A9UD-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR | |
| SLC44A5 | SNV | Missense_Mutation | c.1073N>G | p.Lys358Arg | p.K358R | protein_coding | tolerated(0.16) | benign(0.097) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| SLC44A5 | SNV | Missense_Mutation | c.746N>C | p.Leu249Pro | p.L249P | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | ||
| SLC44A5 | SNV | Missense_Mutation | c.1973N>A | p.Phe658Tyr | p.F658Y | protein_coding | deleterious(0.03) | benign(0.393) | TCGA-AA-3666-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |